Latest From Neurovance Inc.
The US rare diseases company Alexion appoints a new COO and is now looking for a new CFO, head of R&D, and head of human resources, as leadership changes leaves its CEO searching for a new executive team.
Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Neurovance Inc.
- Senior Management
Jeff Bailey, Chmn. & CEO
Catherine O'Brien, Dir., Clinical Operations
William T Pappafotopoulos, VP, Fin. & Admin.
Brian Goff, COO
Anthony McKinney, Chief Dev. Officer
- Contact Info
Phone: (617) 758-0300
43 Thorndike St.
Cambridge, MA 02141
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.